$29.77
11.33% today
Nasdaq, Apr 02, 10:00 pm CET
ISIN
US05370A1088
Symbol
RNA
Sector
Industry

Avidity Biosciences Inc Stock price

$29.77
+0.55 1.88% 1M
-17.35 36.82% 6M
+0.69 2.37% YTD
+2.90 10.79% 1Y
+9.27 45.22% 3Y
+1.27 4.46% 5Y
+1.27 4.46% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+3.03 11.33%
ISIN
US05370A1088
Symbol
RNA
Sector
Industry

Key metrics

Market capitalization $3.21b
Enterprise Value $1.72b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 157.78
P/S ratio (TTM) P/S ratio 294.91
P/B ratio (TTM) P/B ratio 2.25
Revenue growth (TTM) Revenue growth 13.99%
Revenue (TTM) Revenue $10.90m
EBIT (operating result TTM) EBIT $-378.94m
Free Cash Flow (TTM) Free Cash Flow $-307.94m
Cash position $1.50b
EPS (TTM) EPS $-2.90
P/E forward negative
P/S forward 420.41
EV/Sales forward 224.92
Short interest 16.52%
Show more

Is Avidity Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Avidity Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Avidity Biosciences Inc forecast:

14x Buy
100%

Analyst Opinions

14 Analysts have issued a Avidity Biosciences Inc forecast:

Buy
100%

Financial data from Avidity Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
11 11
14% 14%
100%
- Direct Costs 2.78 2.78
35% 35%
26%
8.12 8.12
53% 53%
74%
- Selling and Administrative Expenses 81 81
77% 77%
740%
- Research and Development Expense 304 304
59% 59%
2,785%
-376 -376
63% 63%
-3,451%
- Depreciation and Amortization 2.78 2.78
35% 35%
26%
EBIT (Operating Income) EBIT -379 -379
61% 61%
-3,476%
Net Profit -322 -322
52% 52%
-2,957%

In millions USD.

Don't miss a Thing! We will send you all news about Avidity Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Avidity Biosciences Inc Stock News

Neutral
PRNewsWire
one day ago
SAN DIEGO , April 1, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate in a fireside chat during the following investor conference: 24th Annual Needham Virtual Healthcare Conference on Tuesday...
Neutral
PRNewsWire
2 days ago
Del-brax FORTITUDE biomarker cohort designed for potential accelerated approval; plan to share regulatory update in Q2 2025 Regulatory alignment on global Phase 3 del-brax trial design and study initiation anticipated in Q2 2025 Plan to present topline data from FORTITUDE dose escalation cohorts in Q2 2025 On track to be first globally approved drug for FSHD SAN DIEGO , March 31, 2025 /PRNewswi...
Neutral
PRNewsWire
12 days ago
SAN DIEGO , March 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on March 20, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate...
More Avidity Biosciences Inc News

Company Profile

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) designed to treat a range of serious diseases. The company's lead product candidate is AOC 1001 for treatment of myotonic dystrophy type 1; and four other muscle programs, which focus on the treatment of muscle atrophy, duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. It utilizes its proprietary AOC platform to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. The company also has development programs that focuses on immune and other cell types. Avidity Biosciences, Inc. was founded in 2012 and is based in La Jolla, California.

Head office United States
CEO Sarah Boyce
Employees 391
Founded 2012
Website www.aviditybiosciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today